The MPTP-treated primate as a model of motor complications in PD
Primate model of motor complications
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Motor complications are a common cause of treatment failure in Parkinson’s disease (PD). Although the underlying mechanisms remain obscure, research with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates may facilitate their investigation. Repeated administration of l-dopa to MPTP-treated primates results in a loss of drug efficacy (“wearing off”) and periods of immobility (“on-off”). Immediately after each dose of l-dopa, animals show an initial worsening of motor performance (“beginning-of-dose deterioration”) and, at the end of action of each dose, they exhibit a decline to levels of disability below those seen at baseline (“rebound worsening”). Dyskinesia (chorea, dystonia, athetosis) appears rapidly in MPTP-treated primates given l-dopa. The greater the degree of nigral denervation, the less exposure to l-dopa that is required to induce dyskinesia. The onset and intensity of dyskinesia are related to the dose and frequency of l-dopa administration. Increasing brain exposure to l-dopa increases the severity and intensity of involuntary movements. In contrast, long-acting dopamine agonists (DAs) induce a far lower incidence of dyskinesia, and continuous dopaminergic stimulation may provide a means of avoiding its onset. Recent data from MPTP-treated primates suggest that switching from l-dopa to a long-acting DA may reverse the priming process associated with induction of dyskinesia. Responses of MPTP-treated primates have proved to be highly predictive of antiparkinsonian activities of drugs in humans and their ability to induce dyskinesia, but they may also have utility in evaluating the mechanisms that underlie a range of long-term motor complications affecting patients with PD.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- MPTP-treated primates.
- Motor complications in MPTP-treated primates.
- Dyskinesia in MPTP-treated primates.
- Denervation and dyskinesia.
- l-dopa dose, frequency of administration, and brain exposure.
- Dopamine agonists, dyskinesia, and continuous dopaminergic stimulation.
- Reversal of priming for dyskinesia.
- Conclusions.
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Avoidance of dyskinesiaPreclinical evidence for continuous dopaminergic stimulationPeter Jenner et al.Neurology, January 12, 2004 -
Treatment Guidelines
Management of Parkinson's diseaseet al.Neurology, March 01, 1998 -
Article
The scientific and clinical basis for the treatment of Parkinson disease (2009)C. Warren Olanow, Matthew B. Stern, Kapil Sethi et al.Neurology, May 26, 2009 -
Articles
An algorithm (decision tree) for the management of Parkinson’s disease (2001):Treatment GuidelinesC. Warren Olanow, Ray L. Watts, William C. Koller et al.Neurology, June 12, 2001